# Can-Fite BioPharma Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Can-Fite BioPharma Ltd.). ## Overview Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing orally administered small-molecule therapeutics based on its A3 adenosine receptor platform. Its pipeline is focused on oncology, liver disease, and inflammatory diseases, with development and partnering activities centered in Israel and commercial/regulatory interactions in the United States and Europe. ## Products & services • Namodenoson oncology and liver disease candidate • Piclidenoson inflammatory disease candidate • A3 adenosine receptor platform technology • Clinical development and partnering/licensing rights • Regulatory and commercialization collaborations - **Oncology drug candidates** (40%) — Clinical-stage therapies for cancer indications, including hepatocellular carcinoma and pancreatic cancer. - **Inflammatory disease drug candidates** (30%) — Clinical-stage therapies for autoimmune and inflammatory conditions such as psoriasis. - **Liver disease drug candidates** (20%) — Clinical-stage therapies targeting liver-related diseases including MASH and cirrhosis. - **Licensing and partnering agreements** (10%) — Out-licensing and collaboration agreements that monetize pipeline rights through upfront and milestone payments. - Namodenoson oncology and liver disease candidate - Piclidenoson inflammatory disease candidate - A3 adenosine receptor platform technology - Clinical development and partnering/licensing rights - Regulatory and commercialization collaborations ## Customers Can-Fite sells into a business-to-business pharmaceutical ecosystem rather than directly to patients. Its counterparties are mainly large pharmaceutical companies, biotechnology firms, and potential strategic partners that license drug candidates, fund development, or commercialize assets in specific territories. Ultimately, the therapeutic end users are physicians and patients in oncology, hepatology, and inflammatory disease markets. - **Pharmaceutical licensing partners** (primary) — Large pharma groups that license Namodenoson or Piclidenoson for selected regions or indications to expand pipelines. - **Biotechnology collaboration partners** (primary) — Biotech firms that partner on development, shared trials, or co-commercialization of clinical assets. - **Commercialization partners** (secondary) — Companies that take rights in defined territories and handle market access and launch execution. - **Clinical trial sites and investigators** (secondary) — Hospitals and research centers running the company's Phase II and Phase III studies. - **Patients and treating physicians** (secondary) — Patients with HCC, psoriasis, MASH, pancreatic cancer, or rare disease indications who benefit from the therapies being tested. - Pharmaceutical companies seeking in-licensing opportunities - Biotechnology partners evaluating clinical-stage assets - Strategic partners for regional commercialization - Physicians treating cancer, liver, and inflammatory diseases - Patients enrolled in late-stage clinical trials ## Geography The company is incorporated in Israel and has principal executive offices in Ramat Gan, while its securities trade in the United States on NYSE American and in Israel on TASE. Its development programs are designed for regulatory pathways in the United States and Europe, and partnering activity also includes international licensing arrangements. Clinical and conference-related business activity is visible in the United States, particularly through U.S. regulatory engagement and industry events. - **Israel** (50%) — Corporate headquarters and core development base - **United States** (30%) — Listing, regulatory engagement, and partnering activity - **Europe** (20%) — EMA pathway and potential commercialization territory - Headquartered in Ramat Gan, Israel - Listed on NYSE American and TASE - Regulatory pathways in the United States and Europe - Partnering and conference activity in the United States - Licensing agreements extend across multiple regions ## Strategy Can-Fite’s strategy is to advance a small number of clinical-stage assets through late-stage trials while using partnering and licensing to broaden development reach. The company is also positioning its A3AR platform as a repeatable source of orally administered therapies across oncology, liver disease, and inflammatory disease. Regulatory designations and regional licensing agreements are important because they can reduce development friction and create optionality for future commercialization. - **Late-stage clinical advancement** (short-term) — Phase III data are the main value driver for a clinical-stage biotech and determine partnering leverage. - **Partnering and licensing** (short-term) — Out-licensing can provide non-dilutive capital and territory-specific commercialization capacity. - **Regulatory pathway execution** (medium-term) — FDA and EMA alignment can improve the path to approval and market access for lead assets. - **Platform expansion** (medium-term) — A3AR biology may support additional indications and increase the value of the pipeline. - Advance Namodenoson and Piclidenoson through Phase III - Use licensing to fund and extend development reach - Pursue U.S. and European regulatory pathways - Monetize the A3AR platform across multiple indications - Target oncology, liver disease, and inflammatory disease ## Risks The company depends on successful clinical development of a small number of lead assets, so trial setbacks or weak efficacy data would materially affect valuation. As a biotech with no broad commercial product base, it also faces financing, regulatory, and partnering execution risk, while the biology of oncology and inflammatory disease drug development carries high attrition rates. Any delay in approvals, licensing, or market access would slow the path from pipeline to revenue. - **Late-stage clinical failure** [critical] — Phase III programs are the main value drivers and negative data can sharply reduce future licensing and approval prospects. - **Regulatory approval risk** [high] — FDA and EMA approval depends on meeting predefined efficacy and safety endpoints and may be delayed or denied. - **Financing and dilution risk** [high] — Clinical-stage development is capital intensive and the company may need external funding before commercialization. - **Partnering and licensing execution risk** [medium] — Future monetization depends on finding partners willing to pay upfronts, milestones, and royalties. - Clinical trial failure would materially reduce pipeline value - Regulatory delays can slow approval and partnering - Dependence on a few lead assets concentrates risk - Financing needs are typical for clinical-stage biotech - Partnering execution affects non-dilutive funding and reach ## Accounting As a clinical-stage biotech, Can-Fite’s reported results are heavily shaped by R&D expense recognition, milestone accounting, and the valuation of financing instruments. The company’s licensing deals can create upfront and milestone payments that require careful revenue recognition analysis, while private placements and warrants may involve complex fair value measurements. Share-based compensation, clinical accruals, and any impairment of intangible or platform-related assets are also important judgment areas. - **Revenue recognition for licensing deals** — Affects reported revenue timing and volatility - **Clinical trial accruals** — Affects R&D expense and liabilities - **Warrants and equity-linked instruments** — Affects financing-related gains/losses and balance sheet presentation - **Share-based compensation** — Affects operating expense and diluted share count - R&D expense timing depends on clinical trial accruals and vendor invoices - Licensing upfronts and milestones affect revenue recognition timing - Warrants and private placements may require fair value accounting - Share-based compensation can materially affect operating results - Clinical development estimates drive accruals and liabilities --- *Last updated: 2026-09-28T11:58:09.118533+00:00*